{"id":2091,"date":"2019-10-01T20:19:00","date_gmt":"2019-10-01T18:19:00","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2091"},"modified":"2024-12-13T14:10:30","modified_gmt":"2024-12-13T13:10:30","slug":"neuropharmacology-and-pain-2","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/neuroscience-area\/neuroscience-program\/neuropharmacology-and-pain-2\/","title":{"rendered":"Neuropharmacology and pain"},"content":{"rendered":"\n

\n\t\tNeuropharmacology and pain\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

The group focusses its research on understanding the function of neurotransmitter receptors in health and disease. As such, its main objective is to transfer laboratory results to the patient and to clinical practice. To achieve this, the group strives to find new pharmacological strategies for effective management of neurological, neuropsychiatric, inflammatory and autoimmune diseases and pain.<\/p>\n

496<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"206-neurofarmacologiadolor-fciruela-def\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tOligomerization of receptors, ion channels and proteins interacting in neuropsychiatric diseases and pain.
\nStudy of the functionality of oligomeric interactions in animal models to establish the combined pharmacological treatment bases.
\nClinical evaluation of medications in neuropsychiatric diseases and pain with pharmacoepidemiological methods.\n\t\t\t\t\t
Selected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t